{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:35:49Z","timestamp":1759638949676,"version":"3.40.5"},"reference-count":25,"publisher":"Microbiology Society","issue":"10","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"crossref","award":["HHSO100201600002C"],"award-info":[{"award-number":["HHSO100201600002C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"abstract":"<jats:p>\n                  <jats:bold>Introduction.<\/jats:bold> Ceftobiprole is an advanced-generation broad-spectrum parenteral cephalosporin with activity against MSSA and MRSA.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Gap Statement.<\/jats:bold> Ceftobiprole is not currently approved for use to treat <jats:italic>\n                     <jats:named-content content-type=\"species\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.11043\" xlink:type=\"simple\">S. aureus<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic> bacteremia and phase three clinical trials are taking place. Drug approval requires further pre-clinical evidence to support this new indication.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Aim.<\/jats:bold> The aim of this study was to evaluate the efficacy of ceftobiprole at the human equivalent efficacious exposure (considering a 500\u2009mg q8h dosing regimen infused over 2\u2009h) against MSSA and MRSA strains in a neutropenic murine model of bacteremia and disseminated infection.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Methodology.<\/jats:bold> Two bioluminescent-tagged strains (one MSSA and one MRSA strain) were selected based on their <jats:italic>in vitro<\/jats:italic> susceptibility and <jats:italic>in vivo<\/jats:italic> growth profiles. Bacterial c.f.u. counts in the blood, lung, kidney, and liver were determined 48\u2009h post-infection or after death. The bioluminescent-tag allowed the visualization of the real-time effects of ceftobiprole therapy compared to the natural progression of the infection in untreated controls.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Results.<\/jats:bold> Treatment with ceftobiprole resulted in a significant reduction of the bacterial load with the bioluminescence reduced by 2-log units and bacterial c.f.u. counts reduced by 3- to 6-log units, depending on the organ and bacterial strain. Survival was 100\u200a% in the ceftobiprole-treated group compared to only 0\u201320\u200a%\u2009survival in the untreated control animals for both strains tested.<\/jats:p>\n               <jats:p>\n                  <jats:bold>Conclusion.<\/jats:bold> These results suggest that treatment with ceftobiprole using a 500\u2009mg q8h dosing regimen studied in several successful phase three trials, has potential as an antibiotic therapy to treat bacteremia and associated disseminated infections caused by either methicillin-susceptible or methicillin-resistant strains of <jats:italic>\n                     <jats:named-content content-type=\"species\">\n                        <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/doi.org\/10.1601\/nm.11043\" xlink:type=\"simple\">S. aureus<\/jats:ext-link>\n                     <\/jats:named-content>\n                  <\/jats:italic>.<\/jats:p>","DOI":"10.1099\/jmm.0.001755","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:16:26Z","timestamp":1696418186000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of ceftobiprole in a murine model of bacteremia and disseminated infection"],"prefix":"10.1099","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4141-4140","authenticated-orcid":false,"given":"Charlotte","family":"Cumper","sequence":"first","affiliation":[{"name":"Charles River Laboratories, Portishead, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0916-1786","authenticated-orcid":false,"given":"Claire","family":"Richards","sequence":"additional","affiliation":[{"name":"Charles River Laboratories, Portishead, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Smart","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Allschwil, Swaziland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karine","family":"Litherland","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Allschwil, Swaziland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd, Allschwil, Swaziland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"345","reference":[{"doi-asserted-by":"publisher","key":"R1","DOI":"10.1016\/S0140-6736(19)32989-7"},{"doi-asserted-by":"publisher","key":"R2","DOI":"10.1007\/s12325-017-0622-8"},{"doi-asserted-by":"publisher","key":"R3","DOI":"10.1016\/S0140-6736(18)30696-2"},{"doi-asserted-by":"publisher","key":"R4","DOI":"10.1186\/s13054-017-1801-3"},{"doi-asserted-by":"publisher","key":"R5","DOI":"10.1093\/jac\/dkm258"},{"doi-asserted-by":"publisher","key":"R6","DOI":"10.1007\/s10096-007-0455-5"},{"doi-asserted-by":"publisher","key":"R7","DOI":"10.1128\/mBio.00880-19"},{"key":"R8","first-page":"24","article-title":"Ceftobripole: experience in staphylococcal bacteremia","volume":"32","author":"Soriano","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"R9","first-page":"3","article-title":"Mechanisms of action and antimicrobial activity of ceftobiprole","volume":"32","author":"Morosini","year":"2019","journal-title":"Rev Esp Quimioter"},{"doi-asserted-by":"publisher","key":"R10","DOI":"10.3390\/antibiotics10020170"},{"doi-asserted-by":"publisher","key":"R11","DOI":"10.2217\/fmb-2019-0332"},{"key":"R12","first-page":"341","article-title":"Staphylococcus aureus bacteremia: contemporary management","volume":"117","author":"Abraham","year":"2020","journal-title":"Mo Med"},{"doi-asserted-by":"publisher","key":"R13","DOI":"10.1128\/AAC.01566-18"},{"doi-asserted-by":"publisher","key":"R14","DOI":"10.2165\/00003088-198409060-00001"},{"doi-asserted-by":"publisher","key":"R15","DOI":"10.1128\/IAI.68.6.3594-3600.2000"},{"volume-title":"CLSI Document M07-A9","year":"2012","key":"R16"},{"volume-title":"CLSI Document M100-S24","year":"2014","key":"R17"},{"year":"2018","article-title":"Clinical breakpoints \u2013 bacterial (version 8.0)","key":"R18"},{"doi-asserted-by":"publisher","key":"R19","DOI":"10.1128\/AAC.02566-19"},{"doi-asserted-by":"publisher","key":"R20","DOI":"10.1016\/j.diagmicrobio.2017.12.020"},{"doi-asserted-by":"publisher","key":"R21","DOI":"10.2165\/00003088-200847010-00003"},{"doi-asserted-by":"publisher","key":"R22","DOI":"10.1016\/S0140-6736(21)02724-0"},{"doi-asserted-by":"publisher","key":"R23","DOI":"10.1016\/j.bmc.2016.11.008"},{"key":"R24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1001\/jama.294.7.813","article-title":"Beginning and ending supportive therapy for the kidney (BEST kidney) investigators. acute renal failure in critically ill patients: a multinational, multicenter study","volume":"94","author":"Uchino","year":"2005","journal-title":"J Am Med Assoc"},{"doi-asserted-by":"publisher","key":"R25","DOI":"10.1128\/AAC.01078-12"}],"container-title":["Journal of Medical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001755?crawler=true&mimetype=application\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T11:16:33Z","timestamp":1696418193000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.microbiologyresearch.org\/content\/journal\/jmm\/10.1099\/jmm.0.001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10,4]]}},"URL":"https:\/\/doi.org\/10.1099\/jmm.0.001755","relation":{},"ISSN":["0022-2615","1473-5644"],"issn-type":[{"type":"print","value":"0022-2615"},{"type":"electronic","value":"1473-5644"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}